New developments in natural products-based anti-AIDS research

• Published in: Medicinal research reviews Vol. 27; no. 1; pp. 108 - 132
• Main Authors: Yu, Donglei, Morris-Natschke, Susan L., Lee, Kuo-Hsiung
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2007
• Subjects: 2-ethyl DCP; Acquired Immunodeficiency Syndrome - drug therapy; alkaloids; Alkaloids - therapeutic use; alkaloids, polyphenols; Anti-HIV Agents - chemistry; Anti-HIV Agents - classification; Anti-HIV Agents - therapeutic use; anti-HIV natural products; bevirimat; Coumarins - chemistry; Coumarins - therapeutic use; DCK; Drug Design; DSB (PA-457; DSB (PA‐457, bevirimat); flavonoids; Flavonoids - therapeutic use; HMDCK; Human immunodeficiency virus; Humans; Phenols - therapeutic use; Phytotherapy; Plant Extracts - therapeutic use; Plants, Medicinal - chemistry; Polyphenols; Succinates - chemistry; Succinates - therapeutic use; suksdorfin; Triterpenes - chemistry; Triterpenes - therapeutic use
• ISSN: 0198-6325; 1098-1128
• DOI: 10.1002/med.20075

This review discusses anti‐HIV natural products from several compound classes, including terpenoids, coumarins, alkaloids, polyphenols, tannins, and flavonoids. Natural products can provide novel anti‐AIDS chemotherapeutic leads that are structurally unique or have new mechanisms of action. The drug discovery and development process proceeds from bioactivity‐directed isolation and identification of a promising lead natural product, followed by rational design‐based structural modification and structure–activity relationship analyses to optimize the lead compound as a drug candidate. This process is notably exemplified by the discovery of the modified betulinic acid derivative, DSB [PA‐457], which is currently in Phase II clinical trial and is the first‐in‐class HIV maturation inhibitor (MI). © 2006 Wiley Periodicals, Inc. Med Res Rev, 27, No. 1, 108–132, 2007